Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

first session of receive the newly FDA approved Alzheimer's treatment Leqembi while Williford's wife Cynthia Byron-Williford, 59, right, watches at Abington Neurological Associates in Abington ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

If you'd like to learn more or get involved, the Dallas Walk to End Alzheimer's starts Saturday morning at 8:30 at Dallas ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be unused and discarded, according to a new study published in JAMA ...